{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T23:55:18Z","timestamp":1769212518210,"version":"3.49.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:p>It is over 4 years since the Prospective Comparison of angiotensin receptor\/neprilysin inhibitor (ARNI) with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial was published in New England Journal of Medicine. The PARADIGM-HF trial was the one that contributed to the official approval to use ARNI simultaneously with cardiac resynchronisation therapy (CRT) or implantable cardioverter-defibrillator (ICD) in patients who receive optimal medical treatment and still presented NYHA II-IV class symptoms according to the 2016 European Society of Cardiology Guidelines for the diagnosis and treatment of acute and chronic heart failure. The aim of this article is to summarise current knowledge on the activity of ARNI in a selected group of patients with heart failure with reduced ejection fraction (HFrEF) based on a recent PARADIGM-HF subanalysis in the field of renal function in patients with and without chronic kidney disease, glycaemia control in patients with diabetes, ventricular arrhythmias and sudden cardiac death and health-related quality of life. This article includes also recently announced findings on the TRANSITION study which revealed that HFrEF therapy with ARNI might be safely initiated after an acute decompensated heart failure episode, including patients with heart failure de novo and ACEI\/ARB na\u00efve, both hospitalised or shortly after discharge, in contrary to the PARADIGM-HF trial, where patients had to be administered a stable dose of an ACEI\/ARB equivalent to enalapril 10 mg a day for at least 4 weeks before the screening.<\/jats:p>","DOI":"10.1007\/s10741-019-09879-x","type":"journal-article","created":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T08:03:16Z","timestamp":1573545796000},"page":"393-402","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Angiotensin receptor\/neprilysin inhibitor\u2014a breakthrough in chronic heart failure therapy: summary of subanalysis on PARADIGM-HF trial findings"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7035-4977","authenticated-orcid":false,"given":"Marcin","family":"Ksi\u0105\u017cczyk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u0142gorzata","family":"Lelonek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,12]]},"reference":[{"key":"9879_CR1","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJV McMurray","year":"2014","unstructured":"McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators and Committees (2014) Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993\u20131004. https:\/\/doi.org\/10.1056\/NEJMoa1409077","journal-title":"N Engl J Med"},{"issue":"8","key":"9879_CR2","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonz\u00e1lez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, Authors\/Task Force Members, Document Reviewers (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 18(8):891\u2013975. https:\/\/doi.org\/10.1002\/ejhf.592","journal-title":"Eur J Heart Fail."},{"issue":"23","key":"9879_CR3","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1056\/NEJMc1509753","volume":"373","author":"B Claggett","year":"2015","unstructured":"Claggett B, Packer M, McMurray JJ, Swedberg K, Rouleau J, Zile MR, Jhund P, Lefkowitz M, Shi V, Solomon SD, PARADIGM-HF Investigators (2015) Estimating the long-term treatment benefits of sacubitril-valsartan. N Engl J Med. 373(23):2289\u20132290. https:\/\/doi.org\/10.1056\/NEJMc1509753","journal-title":"N Engl J Med."},{"issue":"5","key":"9879_CR4","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1056\/NEJM199108013250501","volume":"325","author":"SOLVD Investigators","year":"1991","unstructured":"Investigators SOLVD, Yusuf S, Pitt B et al (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 325(5):293\u2013302. https:\/\/doi.org\/10.1056\/NEJM199108013250501","journal-title":"N Engl J Med."},{"key":"9879_CR5","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1056\/NEJMoa010713","volume":"345","author":"JN Cohn","year":"2001","unstructured":"Cohn JN, Tognoni G (2001) A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345:1667\u20131675. https:\/\/doi.org\/10.1056\/NEJMoa010713","journal-title":"N Engl J Med"},{"key":"9879_CR6","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1016\/j.jacc.2007.09.021","volume":"50","author":"LB Daniels","year":"2007","unstructured":"Daniels LB, Maisel AS (2007) Natriuretic peptides. J Am Coll Cardiol 50:2357\u20132368. https:\/\/doi.org\/10.1016\/j.jacc.2007.09.021","journal-title":"J Am Coll Cardiol"},{"key":"9879_CR7","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1007\/BF01726570","volume":"66","author":"P Schulz-Knappe","year":"1988","unstructured":"Schulz-Knappe P, Forssmann K, Herbst F, Hock D, Pipkorn R, Forssmann WG (1988) Isolation and structural analysis of \u201curodilatin\u201d, a new peptide of the cardiodilatin-(ANP)-family, extracted from human urine. Klin Wochenschr 66:752\u2013759. https:\/\/doi.org\/10.1007\/BF01726570","journal-title":"Klin Wochenschr"},{"key":"9879_CR8","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1042\/CS20030366","volume":"106","author":"MT Rademaker","year":"2004","unstructured":"Rademaker MT, Charles CJ, Espiner EA et al (2004) Combined inhibition of angiotensin II and endothelin suppresses the brain natriuretic peptide response to developing heart failure. ClinSci 106:569\u2013576. https:\/\/doi.org\/10.1042\/CS20030366","journal-title":"ClinSci"},{"issue":"17","key":"9879_CR9","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1136\/heartjnl-2014-306775","volume":"102","author":"PS Jhund","year":"2016","unstructured":"Jhund PS, McMurray JJ (2016) The neprilysin pathway in heart failure: a review and guide on the use of sacubitril\/valsartan. Heart. 102(17):1342\u20131347. https:\/\/doi.org\/10.1136\/heartjnl-2014-306775","journal-title":"Heart."},{"key":"9879_CR10","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1016\/j.jacc.2007.09.021","volume":"50","author":"LB Daniels","year":"2007","unstructured":"Daniels LB, Maisel AS (2007) Natriuretic peptides. J Am Coll Cardiol 50:2357\u20132368. https:\/\/doi.org\/10.1016\/j.jacc.2007.09.021","journal-title":"J Am Coll Cardiol"},{"key":"9879_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/1755-5922.12053","volume":"32","author":"JR Dalzell","year":"2014","unstructured":"Dalzell JR, Seed A, Berry C et al (2014) Effects of neutral endopeptidase (neprilysin) inhibition on the response to other vasoactive peptides in small human resistance arteries: studies with thiorphan and omapatrilat. Cardiovasc Ther 32:13\u201318. https:\/\/doi.org\/10.1111\/1755-5922.12053","journal-title":"Cardiovasc Ther"},{"issue":"8","key":"9879_CR12","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.jchf.2015.03.010","volume":"3","author":"A Bay\u00e9s-Gen\u00eds","year":"2015","unstructured":"Bay\u00e9s-Gen\u00eds A (2015) Neprilysin in heart failure: from oblivion to center stage. JACC Heart Fail. 3(8):637\u2013640. https:\/\/doi.org\/10.1016\/j.jchf.2015.03.010","journal-title":"JACC Heart Fail."},{"issue":"11","key":"9879_CR13","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/j.jacc.2019.01.018","volume":"73","author":"PL Myhre","year":"2019","unstructured":"Myhre PL, Vaduganathan M, Claggett B, Packer M, Desai AS, Rouleau JL, Zile MR, Swedberg K, Lefkowitz M, Shi V, McMurray J, Solomon SD (2019) B-Type natriuretic peptide during treatment with sacubitril\/valsartan: the PARADIGM-HF trial. J Am Coll Cardiol. 73(11):1264\u20131272. https:\/\/doi.org\/10.1016\/j.jacc.2019.01.018","journal-title":"J Am Coll Cardiol."},{"issue":"11","key":"9879_CR14","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.jacc.2018.12.063","volume":"73","author":"NE Ibrahim","year":"2019","unstructured":"Ibrahim NE, McCarthy CP, Shrestha S, Gaggin HK, Mukai R, Szymonifka J, Apple FS, Burnett JC Jr, Iyer S, Januzzi JL Jr (2019) Effect of neprilysin inhibition on various natriuretic peptide assays. J Am Coll Cardiol. 73(11):1273\u20131284. https:\/\/doi.org\/10.1016\/j.jacc.2018.12.063","journal-title":"J Am Coll Cardiol."},{"issue":"11","key":"9879_CR15","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1111\/j.1742-4658.2011.08082","volume":"278","author":"LR Potter","year":"2011","unstructured":"Potter LR (2011) Natriuretic peptide metabolism, clearance and degradation. FEBS J. 278(11):1808\u20131817. https:\/\/doi.org\/10.1111\/j.1742-4658.2011.08082","journal-title":"FEBS J."},{"issue":"2","key":"9879_CR16","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.jmb.2009.08.025","volume":"393","author":"K Pankow","year":"2009","unstructured":"Pankow K, Schwiebs A, Becker M, Siems WE, Krause G, Walther T (2009) Structural substrate conditions required for neutral endopeptidase-mediated natriuretic peptide degradation. J Mol Biol. 393(2):496\u2013503. https:\/\/doi.org\/10.1016\/j.jmb.2009.08.025","journal-title":"J Mol Biol."},{"issue":"1","key":"9879_CR17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1006\/bmme.1997.2584","volume":"61","author":"Y Watanabe","year":"1997","unstructured":"Watanabe Y, Nakajima K, Shimamori Y, Fujimoto Y (1997) Comparison of the hydrolysis of the three types of natriuretic peptides by human kidney neutral endopeptidase 24.11. Biochem Mol Med. 61(1):47\u201351","journal-title":"Biochem Mol Med."},{"key":"9879_CR18","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861\u2013869","journal-title":"N Engl J Med"},{"key":"9879_CR19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/ejhf.13","volume":"16","author":"H Clark","year":"2014","unstructured":"Clark H, Krum H, Hopper I (2014) Worsening renal function during 16ennin-angiotensin-aldosterone system inhibitor initiation and long-term outcomes in patients with left ventricular systolic dysfunction. Eur J Heart Fail 16:41\u201348. https:\/\/doi.org\/10.1002\/ejhf.13","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"9879_CR20","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","volume":"6","author":"K Damman","year":"2018","unstructured":"Damman K, Gori M, Claggett B, Jhund PS, Senni M, Lefkowitz MP, Prescott MF, Shi VC, Rouleau JL, Swedberg K, Zile MR, Packer M, Desai AS, Solomon SD, McMurray J (2018) Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. JACC Heart Fail. 6(6):489\u2013498. https:\/\/doi.org\/10.1016\/j.jchf.2018.02.004","journal-title":"JACC Heart Fail."},{"issue":"7","key":"9879_CR21","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S2213-8587(18)30100-1","volume":"6","author":"M Packer","year":"2018","unstructured":"Packer M, Claggett B, Lefkowitz MP, McMurray J, Rouleau JL, Solomon SD, Zile MR (2018) Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the ennin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 6(7):547\u2013554. https:\/\/doi.org\/10.1016\/S2213-8587(18)30100-1","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"9879_CR22","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1001\/jamacardio.2016.4733","volume":"2","author":"AS Desai","year":"2017","unstructured":"Desai AS, Vardeny O, Claggett B et al (2017) Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril\/valsartan compared with enalapril. A secondary analysis of the PARADIGM-HF Trial. JAMA Cardiol. 2(1):79\u201385. https:\/\/doi.org\/10.1001\/jamacardio.2016.4733","journal-title":"JAMA Cardiol."},{"key":"9879_CR23","unstructured":"Masoudi FA, MD, MSPH, FACC, FAHA reviewing Desai AS et al. JAMA Cardiol 2016 Nov 14 Ezekowitz JA. JAMA Cardiol 2016 Nov 14 Does sacubitril\/valsartan reduce hyperkalemia in HFrEF patients taking MRAs? https:\/\/www.jwatch.org\/na42871\/2016\/12\/20\/does-sacubitril-valsartan-reduce-hyperkalemia-hfref. Accessed 28 Aug 2019"},{"key":"9879_CR24","doi-asserted-by":"publisher","unstructured":"Ezekowitz JA (2016) Hyperkalemia, sacubitril\/valsartan, and mineralocorticoid antagonists in patients with heart failure. JAMA Cardiol. https:\/\/doi.org\/10.1001\/jamacardio.2016.4731","DOI":"10.1001\/jamacardio.2016.4731"},{"key":"9879_CR25","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1016\/j.amjcard.2012.02.022","volume":"109","author":"GS Tomova","year":"2012","unstructured":"Tomova GS, Nimbal V, Horwich TB (2012) Relation between hemoglobin (1c) and outcomes in heart failure patients with and without diabetes mellitus. Am J Cardiol. 109:1767\u20131773. https:\/\/doi.org\/10.1016\/j.amjcard.2012.02.022","journal-title":"Am J Cardiol."},{"issue":"5","key":"9879_CR26","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S2213-8587(17)30087-6","volume":"5","author":"JP Seferovic","year":"2017","unstructured":"Seferovic JP, Claggett B, Seidelmann SB et al (2017) Effect of sacubitril\/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol 5(5):333\u2013340. https:\/\/doi.org\/10.1016\/S2213-8587(17)30087-6","journal-title":"Lancet Diabetes Endocrinol"},{"key":"9879_CR27","doi-asserted-by":"publisher","unstructured":"Kristensen SL, Preiss D, Jhund PS et al (2016) Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. Circ Heart Fail 9(1). https:\/\/doi.org\/10.1161\/cirheartfailure.115.002560","DOI":"10.1161\/cirheartfailure.115.002560"},{"issue":"6","key":"9879_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15761\/IOD.1000196","volume":"3","author":"C Chrysohoou","year":"2017","unstructured":"Chrysohoou C, Tousoulis D (2017) The role of sacubitril\/valsartan therapy on renal function and glucose metabolism in chronic heart failure patients. Integr Obesity Diabetes 3(6):1\u20136. https:\/\/doi.org\/10.15761\/IOD.1000196","journal-title":"Integr Obesity Diabetes"},{"key":"9879_CR29","doi-asserted-by":"publisher","unstructured":"Heinisch BB, Vila G, Resl M, Riedl M, Dieplinger B, Mueller T, Luger A, Pacini G, Clodi M B-type natriuretic peptide (BNP) affects the initial response to intravenous glucose: a randomised placebo-controlled cross-over study in healthy men. Diabetologia. 55(5):1400\u20131405. https:\/\/doi.org\/10.1007\/s00125-011-2392-1","DOI":"10.1007\/s00125-011-2392-1"},{"issue":"12","key":"9879_CR30","doi-asserted-by":"publisher","first-page":"4675","DOI":"10.1172\/JCI64526","volume":"122","author":"S Engeli","year":"2012","unstructured":"Engeli S, Birkenfeld AL, Badin PM, Bourlier V, Louche K, Viguerie N, Thalamas C, Montastier E, Larrouy D, Harant I, de Glisezinski I, Lieske S, Reinke J, Beckmann B, Langin D, Jordan J, Moro C (2012) Natriuretic peptides enhance the oxidative capacity of human skeletal muscle. J Clin Invest. 122(12):4675\u20134679. https:\/\/doi.org\/10.1172\/JCI64526","journal-title":"J Clin Invest."},{"issue":"9","key":"9879_CR31","doi-asserted-by":"publisher","first-page":"e44782","DOI":"10.1371\/journal.pone.0044782","volume":"7","author":"MA Mori","year":"2012","unstructured":"Mori MA, Sales VM, Motta FL et al (2012) Kinin B1 receptor in adipocytes regulates glucose tolerance and predisposition to obesity. PLoS One 7(9):e44782","journal-title":"PLoS One"},{"issue":"9","key":"9879_CR32","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1007\/s00125-005-1847-7","volume":"48","author":"A Plamboeck","year":"2005","unstructured":"Plamboeck A, Holst JJ, Carr RD et al (2005) Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia 48(9):1882\u20131890","journal-title":"Diabetologia"},{"issue":"4","key":"9879_CR33","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s00125-016-4172-4","volume":"60","author":"JR Willard","year":"2017","unstructured":"Willard JR, Barrow BM, Zraika S et al (2017) Improved glycaemia in high-fat-fed neprilysin-deficient mice is associated with reduced DPP-4 activity and increased active GLP-1 levels. Diabetologia. 60(4):701\u2013708. https:\/\/doi.org\/10.1007\/s00125-016-4172-4","journal-title":"Diabetologia."},{"issue":"6","key":"9879_CR34","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1002\/ejhf.1185","volume":"20","author":"M Packer","year":"2018","unstructured":"Packer M (2018) Augmentation of glucagon-like peptide-1 receptor signalling by neprilysin inhibition: potential implications for patients with heart failure. Eur J Heart Fail. 20(6):973\u2013977. https:\/\/doi.org\/10.1002\/ejhf.1185","journal-title":"Eur J Heart Fail."},{"issue":"30","key":"9879_CR35","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1093\/eurheartj\/ehv186","volume":"36","author":"AS Desai","year":"2015","unstructured":"Desai AS, McMurray J, Packer M, Swedberg K, Rouleau JL, Chen F, Gong J, Rizkala AR, Brahimi A, Claggett B, Finn PV, Hartley LH, Liu J, Lefkowitz M, Shi V, Zile MR, Solomon SD (2015) Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J. 36(30):1990\u20131997. https:\/\/doi.org\/10.1093\/eurheartj\/ehv186","journal-title":"Eur Heart J."},{"issue":"6","key":"9879_CR36","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1161\/circulationaha.118.034755","volume":"138","author":"A Sarrias","year":"2018","unstructured":"Sarrias A, Bayes-Genis A (2018) Is sacubitril\/valsartan (also) an antiarrhythmic drug? Circulation. 138(6):551\u2013553. https:\/\/doi.org\/10.1161\/circulationaha.118.034755","journal-title":"Circulation."},{"issue":"3","key":"9879_CR37","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.hrthm.2017.11.012","volume":"15","author":"C de Diego","year":"2018","unstructured":"de Diego C, Gonz\u00e1lez-Torres L, N\u00fa\u00f1ez JM, Centuri\u00f3n Inda R, Martin-Langerwerf DA, Sangio AD, Chochowski P, Casasnovas P, Blazqu\u00e9z JC, Almendral J (2018) Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices. Heart Rhythm. 15(3):395\u2013402. https:\/\/doi.org\/10.1016\/j.hrthm.2017.11.012","journal-title":"Heart Rhythm."},{"issue":"3","key":"9879_CR38","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.hrthm.2017.11.029","volume":"15","author":"JR Ehrlich","year":"2018","unstructured":"Ehrlich JR (2018) Do we still need ICDs if we have ARNi? Heart Rhythm 15(3):403\u2013404. https:\/\/doi.org\/10.1016\/j.hrthm.2017.11.029","journal-title":"Heart Rhythm"},{"issue":"5","key":"9879_CR39","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S0735-1097(00)00531-3","volume":"35","author":"CP Green","year":"2000","unstructured":"Green CP, Porter CB, Bresnahan DR, Spertus JA (2000) Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol. 35(5):1245\u20131255","journal-title":"J Am Coll Cardiol."},{"key":"9879_CR40","doi-asserted-by":"publisher","unstructured":"Lewis EF, Claggett BL, McMurray JJV et al (2017) Health-related quality of life outcomes in PARADIGM-HF. Circ Heart Fail 10(8). https:\/\/doi.org\/10.1161\/circheartfailure.116.003430","DOI":"10.1161\/circheartfailure.116.003430"},{"issue":"6","key":"9879_CR41","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1001\/jamacardio.2018.0398","volume":"3","author":"A Chandra","year":"2018","unstructured":"Chandra A, Lewis EF, Claggett BL, Desai AS, Packer M, Zile MR, Swedberg K, Rouleau JL, Shi VC, Lefkowitz MP, Katova T, McMurray J, Solomon SD (2018) Effects of sacubitril\/valsartan on physical and social activity limitations in patients with heart failure: a secondary analysis of the PARADIGM-HF trial. JAMA Cardiol. 3(6):498\u2013505. https:\/\/doi.org\/10.1001\/jamacardio.2018.0398","journal-title":"JAMA Cardiol."},{"key":"9879_CR42","doi-asserted-by":"crossref","unstructured":"Wachter R, Senni M, Belohlavek J, et al. Initiation of sacubitril\/valsartan in hospitalized patients with HFrEF after hemodynamic stabilization: Baseline characteristics of the TRANSITION study compared with TITRATION and PARADIGM-HF. Poster P6531 presented at ESC congress, Munich, Germany, 25-29 August 2018","DOI":"10.1093\/eurheartj\/ehy566.P6531"},{"key":"9879_CR43","doi-asserted-by":"crossref","unstructured":"Wachter R, Senni M, Belohlavek J, et al. Initiation of sacubitril\/valsartan in hospitalized patients with heart failure with reduced ejection fraction after hemodynamic stabilization: Primary results of the TRANSITION study. Poster P886 presented at ESC Congress, Munich, Germany, 25-29, 2018 August, 2018","DOI":"10.1093\/eurheartj\/ehy564.P886"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-019-09879-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10741-019-09879-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-019-09879-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T00:48:12Z","timestamp":1605055692000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10741-019-09879-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,12]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["9879"],"URL":"https:\/\/doi.org\/10.1007\/s10741-019-09879-x","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"value":"1382-4147","type":"print"},{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,12]]},"assertion":[{"value":"12 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Ma\u0142gorzata Lelonek participated in clinical trials with molecule LCZ696. Marcin Ksi\u0105\u017cczyk declares that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}